Clinical Guides
Bacterial Vaginosis
A clinically focused clinical guide to recognising bacterial vaginosis, confirming the diagnosis, selecting India-appropriate treatment and managing pregnancy, recurrence and important alternative diagnoses.
MedNext Academy | 16 min read
Bacterial Vaginosis
A clinically focused clinical guide to recognising bacterial vaginosis, confirming the diagnosis, selecting India-appropriate treatment and managing pregnancy, recurrence and important alternative diagnoses.
Summary
Bacterial vaginosis (BV) is a vaginal dysbiosis in which lactobacillus-predominant flora is replaced by a diverse community of anaerobic and other BV-associated bacteria. It is not simply infection by Gardnerella and is not classified as a conventional sexually transmitted infection, although sexual exposures influence risk and BV is associated with increased acquisition of several STIs. Many people are asymptomatic. Symptomatic BV classically causes a thin homogeneous discharge and a fishy odour, often more noticeable after intercourse or during menstruation; marked vulval inflammation is less typical and should prompt consideration of another or mixed diagnosis.
Diagnosis should be established with validated clinical or laboratory criteria rather than odour or discharge colour alone. Amsel diagnosis uses four features: homogeneous discharge, vaginal pH above 4.5, clue cells on microscopy and a fishy amine odour before or after adding potassium hydroxide; at least three support BV. Nugent scoring of a Gram-stained smear is a laboratory reference method. Validated nucleic-acid amplification tests can diagnose BV in symptomatic patients, but culture of Gardnerella is not specific because it may be present without disease. Candida, trichomoniasis, cervicitis, retained foreign body and non-infectious vaginitis can mimic or coexist.
Treat symptomatic BV to relieve symptoms. WHO 2024 suggests oral metronidazole 400 or 500 mg twice daily for seven days for adults and adolescents, including pregnant patients, with oral or vaginal alternatives according to availability, adherence, contraindications and preference. Recurrence is common and does not automatically prove non-adherence or reinfection. Douching and unnecessary intravaginal products should stop. STI testing is offered according to national and individual risk. Repeated empirical therapy without diagnostic review can miss trichomoniasis, cervicitis, Candida, pelvic inflammatory disease or a non-infectious disorder. This guide is educational; a registered clinician must verify pregnancy, allergies, interactions, Indian licensing and the current NACO algorithm before prescribing.
How Common Is It?
BV is one of the most common causes of abnormal vaginal discharge during reproductive life. The WHO 2025 fact sheet cites a pooled global prevalence range of approximately 23% to 29% among reproductive-age women, but this is not an India-specific clinic prediction. Prevalence varies by country, population, pregnancy status, sexual networks, vaginal practices, diagnostic method and whether asymptomatic people are screened. Amsel criteria, Nugent score and molecular panels do not identify identical populations. A national or local percentage should therefore include its population and test rather than being applied to every patient.
Many cases are asymptomatic, so anatomical prevalence exceeds clinical attendance. Conversely, symptomatic clinics over-represent recurrent, pregnant or mixed disease. NACO's 2024 STI/RTI guideline includes BV among the common causes of vaginal discharge syndrome in India and uses enhanced syndromic management where etiological testing is unavailable. That programme approach establishes service relevance, not that all vaginal discharge is BV. Physiological secretion, Candida and trichomoniasis remain common alternatives, and cervicitis may not present predictably.
BV has importance beyond odour. WHO and CDC associate it with increased susceptibility to HIV and other STIs and with adverse pregnancy outcomes, although treating every asymptomatic person has not been shown to improve every possible outcome. Risk associations do not mean BV is proof of infidelity. Recurrence after apparently successful therapy is frequent because the vaginal ecological state, biofilm and exposures can persist or re-establish.
The clinical burden includes embarrassment, avoidance of sex, repeated self-treatment and stigma. A high-quality service normalises consultation, protects privacy and avoids describing BV as dirty hygiene. Internal washing can worsen rather than prevent it. Population screening is not routine for all asymptomatic people; testing and treatment are driven by symptoms, pregnancy or procedure context and current guidance. The practical question is not merely how common BV is, but whether this patient's findings meet diagnostic criteria and whether another condition needs treatment.
Risk Factors
BV develops through a shift in vaginal microbial ecology rather than invasion by one pathogen. Associated factors include a new sexual partner, multiple partners, condomless sex, female partners with BV and vaginal douching or insertion practices. BV can occur without recent sexual activity, so sexual transmission should not be asserted as the sole mechanism. WHO highlights excessive vaginal cleansing and insertion of herbs or other products as modifiable risks. Menstruation, recent intercourse and semen can transiently affect pH and odour and can influence testing.
Copper-containing intrauterine contraception has been associated with higher BV prevalence in some studies, whereas hormonal contraception does not appear to increase risk and may be protective in some populations. This association is not a reason to remove a well-functioning device automatically. Pregnancy changes the importance of symptoms and medicine selection. Antibiotic exposure, local products and recent BV treatment can alter microscopy or molecular results. Smoking has epidemiological associations, but cessation advice should be offered for overall health without promising that it will prevent every recurrence.
Recurrence risk is substantial after any effective regimen. Persistent biofilm, failure to re-establish lactobacillus dominance, ongoing douching, sexual exchange of BV-associated organisms and an incorrect or mixed original diagnosis may contribute. Current partner-treatment evidence is evolving; older guidance does not recommend routine treatment of male partners, while newer trials have changed discussion in some settings. Indian care should follow the current NACO recommendation and specialist advice rather than extrapolate a trial into an unsupervised partner prescription.
Risk of complications differs from risk of BV itself. Pregnancy, HIV exposure, planned gynaecological procedures, PID symptoms and recurrent disease increase the need for careful assessment. A fishy smell without examination can also come from trichomoniasis or a retained foreign body. Risk factors never replace diagnostic criteria. Ask about practices and partners neutrally, explain why the questions matter and avoid equating BV with poor personal hygiene.
Diagnosis
Diagnose BV in a symptomatic patient using clinical criteria, Gram stain or a validated molecular test. A remote diagnosis or a self-recognised odour is not sufficient when symptoms are atypical, recurrent or treatment-resistant. Collect samples before antimicrobials when feasible, but do not delay urgent PID or pregnancy care.
History
Characterise change from baseline, onset, thin versus thick consistency, grey-white colour and fishy odour, including relation to intercourse or menses. Ask about itch, soreness, external dysuria, dyspareunia, lower abdominal pain, fever, bleeding and urinary symptoms; prominent itch or vulval swelling points more strongly toward Candida or mixed disease. Record last menstrual period, pregnancy possibility, contraception, postpartum state, new or multiple partners, barrier use, female partners, previous STI, douching, intravaginal products, antibiotics and self-treatment. For recurrence, document test-confirmed episodes, exact regimens, adherence and time to return.
Examination
With consent and a chaperone, inspect the vulva for erythema, fissures, lesions or dermatosis. BV alone often has little vulval inflammation. Speculum examination assesses thin homogeneous coating of the vaginal walls, discharge origin, cervicitis, bleeding, retained material and lesions. Lower abdominal pain, fever or dyspareunia requires abdominal and bimanual assessment for PID, including cervical-motion, uterine or adnexal tenderness. Pregnancy with pain or bleeding changes urgency.
Investigations
Amsel criteria are: thin homogeneous discharge; pH greater than 4.5; clue cells on saline microscopy; and a fishy amine odour before or after 10% potassium hydroxide. Three of four support BV. Measure pH from the lateral vaginal wall, avoiding cervical mucus, blood or lubricants where possible. Nugent scoring grades Gram-stain morphotypes from 0 to 10, with 7 to 10 consistent with BV and 4 to 6 intermediate. NAAT panels detecting combinations of BV-associated bacteria and lactobacilli have high performance in symptomatic patients; understand the local assay. Do not culture Gardnerella as a diagnostic test. Test for trichomoniasis, Candida, chlamydia, gonorrhoea, HIV and syphilis according to findings and risk. A positive Candida culture without compatible symptoms may represent colonisation.
Differential Diagnosis
Physiological discharge is clear or white, minimally odorous and not associated with irritation. Vulvovaginal candidiasis usually produces more itch, soreness, vulval erythema, fissures and external dysuria; discharge may be thick, and pH is generally below 4.5. Trichomoniasis can produce malodorous yellow-green discharge, irritation, dysuria and cervical punctate erythema, usually with pH above 4.5. A negative wet mount does not exclude it; NAAT is more sensitive. Mixed BV and Candida or BV and trichomoniasis can occur, so an atypical inflammatory picture should not be forced into one label.
Cervicitis from chlamydia, gonorrhoea or other causes may present with endocervical mucopus, friability or postcoital bleeding, but can be asymptomatic. Vaginal discharge alone predicts it poorly. Lower abdominal pain, fever, deep dyspareunia or cervical-motion, uterine or adnexal tenderness raises concern for PID and requires prompt treatment. Genital ulcers, a cervical lesion or postmenopausal bleeding are separate pathways.
A retained tampon, condom or other foreign body is an important cause of offensive discharge, sometimes blood-stained. Genitourinary syndrome of menopause produces dryness, burning, dyspareunia and raised pH, which can be mistaken for BV. Desquamative inflammatory vaginitis and aerobic vaginitis also cause raised pH but typically show inflammation, parabasal cells or altered aerobic flora rather than classic clue-cell BV. Irritant or allergic vulvovaginitis follows soaps, antiseptics, pads, lubricants or repeated topical medicine.
Urinary or faecal fistula causes continuous leakage and offensive symptoms. Cervical or endometrial malignancy can cause watery, blood-stained or offensive discharge, particularly after menopause. In pregnancy, rupture of membranes is not vaginal discharge and needs obstetric evaluation. Accurate diagnosis therefore combines the vaginal microbial pattern with cervix, upper tract, tissue state and patient context. A raised pH alone is not BV, and the presence of Gardnerella alone is not disease.
Management
Treat symptomatic BV with an evidence-based antibacterial regimen and clear expectations. Explain that symptoms usually improve, recurrence is common and BV is not proof of an STI or infidelity. Advise stopping vaginal douching, antiseptic washes, steaming and insertion of herbs or other products. External gentle cleansing is sufficient. During treatment, follow current advice on sex and barrier use; intravaginal clindamycin products may weaken latex temporarily. Offer HIV and other STI testing according to NACO guidance and individual exposure.
Use etiological treatment when Amsel, Nugent or a validated molecular test supports BV. In a setting without diagnostic access, apply the 2024 NACO enhanced syndromic vaginal-discharge algorithm after screening for pregnancy, cervicitis risk, lower abdominal pain and red flags. Tell the patient that syndromic treatment covers several common causes but does not confirm each one. Avoid repeating a combination kit for every recurrence without examination or testing.
Treat symptomatic pregnant patients with a recommended pregnancy-compatible regimen. Do not screen or treat all asymptomatic pregnant people outside current obstetric guidance merely because BV is associated with adverse outcomes. Coordinate care for previous preterm birth, current pregnancy complications or procedure planning. For first recurrence, a different recommended regimen or retreatment may be reasonable after confirming the diagnosis and adherence. Multiple recurrences require specialist review of microscopy or NAAT, exposures, alternative diagnoses and suppressive options.
Probiotic products and vaginal microbiome products should not replace recommended antibiotics; evidence, formulation quality and availability vary. Boric acid is not a routine first-line BV treatment, is toxic if swallowed and must not be used in pregnancy. Current partner-treatment evidence should be discussed honestly: routine partner treatment has historically not been recommended in CDC guidance, while newer evidence is developing. Follow current Indian national or specialist advice rather than treating partners with improvised antibiotics. Review is unnecessary after uncomplicated symptom resolution, but return promptly for recurrent odour, pain, fever, bleeding, pregnancy concerns or treatment intolerance.
Prescribing Information
For adults and adolescents with BV, including pregnant patients, WHO 2024 suggests metronidazole 400 mg or 500 mg orally twice daily for seven days. The exact strength available in India and local NACO protocol determine the prescribed tablet. Explain dosing, completion and common gastrointestinal or metallic-taste effects. Check allergy, significant liver disease, interacting medicines and individual alcohol advice against the current product label; evidence does not support inventing a prolonged abstinence interval beyond authoritative labelling.
When oral metronidazole is unavailable, adherence to multiple doses is a serious concern or vaginal treatment is preferred, WHO alternatives include metronidazole 0.75% gel intravaginally for seven days; clindamycin 300 mg orally twice daily for seven days; clindamycin 2% cream 5 g intravaginally daily for seven days; secnidazole 2 g orally once; or tinidazole 2 g orally once outside pregnancy. CDC regimens differ slightly for some vaginal durations. Use one current guideline deliberately, not a hybrid regimen. Verify Indian approval, product directions, pregnancy and breastfeeding suitability and cost.
Clindamycin cream and some intravaginal products are oil-based and may weaken latex condoms or diaphragms for a product-specific interval. Tinidazole should not be used in pregnancy under the WHO option stated here. Intravaginal treatment may cause local irritation; oral clindamycin carries antibiotic-associated diarrhoea risk. Do not prescribe culture-directed therapy from a Gardnerella culture because it lacks diagnostic specificity.
For recurrent BV, confirm BV again before suppression. CDC describes options such as metronidazole gel twice weekly for more than three months in selected multiple recurrences, but benefits may stop after suppression and specialist oversight is prudent. More complex regimens involving oral nitroimidazole, intravaginal boric acid and suppressive gel are limited-evidence options, not a routine online prescription; boric acid must never be swallowed and is contraindicated in pregnancy. If symptoms persist, check adherence, test for trichomoniasis and Candida, examine for cervicitis or foreign body and reconsider non-infectious vaginitis before extending antibiotics.
When to Refer
Refer urgently for pregnancy with abdominal pain, bleeding, fever or possible ruptured membranes; severe lower abdominal pain; cervical-motion, uterine or adnexal tenderness with systemic illness; suspected tubo-ovarian abscess; sepsis; inability to tolerate oral treatment; or haemodynamic instability. These presentations may be PID, ectopic pregnancy or obstetric disease rather than uncomplicated BV. Provide emergency stabilisation and do not wait for a BV result.
Use urgent gynaecology assessment for postmenopausal bleeding, persistent blood-stained or watery discharge, a suspicious cervical or vulval lesion, pelvic mass, retained foreign body that cannot be removed safely or suspected fistula. A child with malodorous discharge, bleeding or possible foreign body requires paediatric and safeguarding care. Severe vulval inflammation, ulcers or necrosis is not typical isolated BV and warrants broader evaluation.
Refer to sexual-health or gynaecology expertise for repeated laboratory-confirmed recurrence, treatment failure after adherence, pregnancy with recurrent symptoms, HIV or substantial immunosuppression, uncertain microscopy, mixed vaginitis, suspected desquamative inflammatory or aerobic vaginitis, or persistent symptoms with negative tests. NACO Suraksha Clinics can provide India-specific etiological testing, HIV and syphilis services and partner counselling.
Specialist discussion is appropriate before prolonged suppressive metronidazole, boric-acid-containing protocols or partner treatment outside current national recommendations. Refer when the chosen agent is not clearly licensed or available in India, when interactions are complex or when repeated antimicrobial exposure is causing harm. Send the diagnostic criteria, tests, previous regimens, adherence and recurrence dates with the referral; a label of recurrent BV without evidence invites another empirical cycle rather than a solution.
Red Flags
BV usually causes local discharge and odour without systemic illness. Fever, tachycardia, vomiting, severe pelvic or abdominal pain, guarding, cervical-motion tenderness or adnexal tenderness suggests PID, abscess or another acute abdomen. Pregnancy with pain, bleeding, syncope or shoulder-tip pain requires urgent ectopic-pregnancy assessment. Fluid leakage in pregnancy requires evaluation for membrane rupture. Postpartum or post-procedure offensive discharge with fever may represent endometritis.
Bleeding is not a routine BV feature. Postmenopausal bleeding, persistent postcoital or intermenstrual bleeding, a friable cervix, blood-stained watery discharge or visible lesion requires directed assessment for cervical, endometrial or vulval disease. An intensely offensive discharge with retained material, systemic toxicity or tissue injury may indicate a foreign body or serious infection. Continuous urine or faecal leakage suggests fistula.
Treatment red flags include facial swelling, breathing difficulty, widespread rash, mucosal blistering, jaundice, severe diarrhoea, focal neurological symptoms or a clinically important interaction. Intravaginal boric acid ingestion is a poisoning emergency. Severe vulval oedema, fissuring and intense itch point away from isolated BV and toward Candida, allergy, dermatosis or mixed disease.
Safeguarding concerns override routine care. Symptoms in a child, sexual assault, coercion, trafficking or inability to speak privately require an appropriate pathway. Recurrence itself becomes a warning when repeated antibiotics are issued without diagnostic criteria, when a partner has untreated trichomoniasis or STI symptoms, or when pain and bleeding are being normalised as BV. Stop, retest and broaden the differential rather than escalating the same treatment.
Indian Clinical Context
NACO's National Technical Guidelines on STI and RTI 2024 are the Indian anchor. They place BV within vaginal discharge syndrome alongside Candida and trichomoniasis, use enhanced syndromic management where immediate etiological diagnosis is unavailable and encourage laboratory support where feasible. Apply the national flowchart including cervicitis-risk and lower-abdominal-pain assessment; do not use an imported regimen when the Indian programme has a current one. Confirm the current colour-coded kit contents rather than relying on memory because programme procurement can change.
At a peripheral facility, pH and microscopy may be unavailable. Syndromic care can prevent loss to follow-up, but counsel that it is a management category rather than proof of multiple infections. At district or tertiary level, use Amsel, Gram stain, validated molecular tests and STI testing to reduce repeated broad therapy. NACO's Suraksha Clinics and regional reference network provide referral routes for etiological diagnosis, HIV and syphilis services and treatment failure.
Counselling must actively remove stigma. BV is not caused by being unclean, and internal antiseptic washing can worsen dysbiosis. It is not definitive evidence of sexual transmission or infidelity. Ask about douching, intravaginal herbs and products without ridicule, then explain the biological reason to stop. Use generic medicines and confirm CDSCO-authorised products, pregnancy labelling, availability and affordability. Do not promote probiotics or commercial washes as cures.
Partner advice must reflect current evidence and Indian guidance. Do not automatically treat an asymptomatic partner using an old kit or a newly publicised trial. Offer STI testing and condoms according to risk, and refer recurrent cases where specialist interpretation is possible. Provide instructions in the patient's preferred language, including dose, duration, potential latex-product effects and return symptoms. A teleconsultation can support follow-up, but recurrent odour, pregnancy, pain, bleeding or uncertain diagnosis often needs specimen collection and examination.
NMC Competency Mapping
OG22.2 in the NMC CBME Curriculum 2024 explicitly names bacterial vaginosis within vaginal discharge aetiology and requires characteristics, clinical diagnosis, investigations, genital hygiene, common-cause management and syndromic management. The learner should describe replacement of lactobacillus-predominant flora by polymicrobial anaerobic communities, without reducing BV to Gardnerella infection or labelling it a conventional STI.
Diagnostic competence includes Amsel criteria, clue cells, pH above 4.5, amine odour and thin homogeneous discharge, with at least three criteria supporting diagnosis. Learners should know Nugent scoring on Gram stain and why Gardnerella culture is not specific. They should distinguish BV from Candida, trichomoniasis and physiological discharge, and recognise cervicitis and PID. OG22.1 provides the physiological comparison; DR10.10 and OG35.5 require case-based diagnosis and management of vaginal discharge.
Management competence is more than writing metronidazole. It includes checking pregnancy and allergies, choosing a current NACO or WHO regimen, counselling against douching, explaining recurrence, offering STI testing according to risk and avoiding routine partner treatment unless current guidance indicates it. MI8.3 supports the concept and utility of syndromic management. A strong answer states when syndrome-based treatment is pragmatic and when microscopy, NAAT or referral improves accuracy.
For an OSCE, obtain a non-judgemental sexual and intravaginal-practice history, identify pelvic pain and bleeding red flags, obtain consent for examination, describe correct lateral-wall pH sampling and interpret clue cells. Explain that BV is treatable and not proof of poor hygiene. Finish with generic dose and duration, pregnancy considerations, barrier-product advice, follow-up for recurrence and escalation for PID or atypical symptoms.
Key Exam Pearls for NEET PG
BV is polymicrobial vaginal dysbiosis with loss of lactobacillus dominance, not a single-organism Gardnerella infection. Amsel requires three of four: thin homogeneous discharge, pH greater than 4.5, clue cells and a fishy amine odour. Nugent score 7 to 10 supports BV, 4 to 6 is intermediate and 0 to 3 is lactobacillus-predominant. Gardnerella culture is not diagnostic. Molecular BV panels are used in symptomatic patients.
BV usually has little vulval inflammation. Prominent itch, erythema, oedema or fissures suggests Candida or mixed vaginitis. Trichomoniasis can also cause raised pH and malodour, so use NAAT where possible. Cervicitis and PID are not excluded by a BV diagnosis. Treat symptomatic BV; do not automatically screen or treat every asymptomatic person.
WHO 2024 first option is metronidazole 400 or 500 mg orally twice daily for seven days, including pregnancy. Know accepted oral and vaginal alternatives but do not mix guideline durations. Tinidazole is excluded from the stated pregnancy options. Clindamycin cream can weaken latex barrier products. BV recurrence is common; confirm diagnosis before suppression. Probiotics are not a substitute for recommended antibiotic treatment.
BV is associated with increased STI acquisition and adverse pregnancy outcomes, but it is not proof of sexual transmission or infidelity. Routine partner treatment has historically not been recommended; evidence is evolving, so follow current national guidance. Red flags are pelvic pain or fever, pregnancy with pain or bleeding, postmenopausal or postcoital bleeding, a retained foreign body and persistent symptoms despite confirmed adherence.
Frequently Asked Questions
Is bacterial vaginosis considered a sexually transmitted infection?
BV is not classified as a conventional STI, although sexual activity, new or multiple partners and condomless sex influence risk, and BV-associated organisms may be exchanged between partners. It can also occur without recent sexual activity. A diagnosis is not evidence of infidelity or poor hygiene. Because BV is associated with higher acquisition of some STIs, clinicians offer appropriate STI testing based on national guidance and the person's exposures rather than treating BV as proof of another infection.
How is bacterial vaginosis confirmed in clinical practice?
BV can be diagnosed using at least three of four Amsel criteria: thin homogeneous discharge, vaginal pH above 4.5, clue cells on microscopy and a fishy amine odour. Nugent scoring of a Gram-stained smear is a laboratory reference method, while validated molecular panels are useful for symptomatic patients. A raised pH or positive Gardnerella culture alone is not diagnostic. Recurrent or atypical symptoms need testing for Candida, trichomoniasis, cervicitis and non-infectious causes.
Why does bacterial vaginosis often return after successful treatment?
Recurrence can follow persistence or re-formation of the BV microbial community and biofilm, failure to restore lactobacillus dominance, ongoing douching or intravaginal practices, sexual exchange of associated organisms, or an incorrect or mixed original diagnosis. It does not automatically mean the patient failed treatment. Repeated episodes should be reconfirmed before suppressive therapy, with review for trichomoniasis, Candida, cervicitis, foreign body and non-infectious vaginitis rather than repeated unsupervised antibiotics.
Can bacterial vaginosis be treated during pregnancy safely?
Yes. Symptomatic BV in pregnancy can be treated with recommended pregnancy-compatible regimens. WHO 2024 suggests oral metronidazole 400 or 500 mg twice daily for seven days for adults and adolescents, including pregnant patients, with suitable alternatives selected by a clinician. Pregnancy status must be confirmed because some alternatives, such as tinidazole in the WHO regimen, are excluded. Pain, bleeding, fever or fluid leakage in pregnancy requires obstetric assessment rather than routine BV treatment alone.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic